Syndax Pharmaceuticals, Inc. (SNDX) – What Are Analysts Saying About This Stock?

Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) have been given an average rating of “Moderate Buy” by the eleven research firms that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating and ten have given a buy rating to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $41.60.

Several equities analysts recently commented on SNDX shares. Mizuho set a $43.00 target price on shares of Syndax Pharmaceuticals in a report on Tuesday, November 3rd. UBS Group reiterated a “buy” rating on shares of Syndax Pharmaceuticals in a research report on Thursday, October 1st. Weiss Ratings raised shares of Syndax Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, November 3rd. Jefferies Financial Group restated a “buy” rating and set a $35.00 price target on shares of Syndax Pharmaceuticals in a research report on Tuesday, September 29th. Finally, Bank of America restated a “buy” rating on shares of Syndax Pharmaceuticals in a research report on Wednesday, August 5th.

Syndax Pharmaceuticals Trading Up 0.1%

Shares of SNDX opened at $9.55 on Tuesday. The stock has a 50 day simple moving average of $16.13 and a two-hundred day simple moving average of $19.96. The company has a quick ratio of 6.44, a current ratio of 4.69 and a debt-to-equity ratio of 38.95. Syndax Pharmaceuticals has a 1 year low of $9.15 and a 1 year high of $25.59.

Syndax Pharmaceuticals (NASDAQ:SNDX) last issued its quarterly earnings results on Monday, November 2nd. The company reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.05). The business had revenue of $83.30 million for the quarter, compared to the consensus estimate of $81.38 million. Syndax Pharmaceuticals had a negative net margin of 72.32% and a negative return on equity of 804.38%. The firm’s revenue was up 81.9% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.70) earnings per share. On average, equities analysts anticipate that Syndax Pharmaceuticals will post -2.09 EPS for the current fiscal year.

Insider Buying and Selling at Syndax Pharmaceuticals

In other news, Director Dennis Podlesak sold 8,000 shares of the business’s stock in a transaction dated Thursday, October 29th. The stock was sold at an average price of $14.21, for a total value of $113,680.00. Following the completion of the sale, the director owned 239,763 shares of the company’s stock, valued at approximately $3,407,032.23. The trade was a 3.23% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 4.80% of the company’s stock.

Hedge Funds Weigh In On Syndax Pharmaceuticals

A number of large investors have recently bought and sold shares of the stock. Hantz Financial Services Inc. bought a new position in shares of Syndax Pharmaceuticals in the third quarter worth approximately $159,000. CenterBook Partners LP purchased a new position in shares of Syndax Pharmaceuticals in the third quarter worth $5,137,000. Mirae Asset Global Investments Co. Ltd. bought a new stake in Syndax Pharmaceuticals during the 3rd quarter valued at $86,000. China Universal Asset Management Co. Ltd. raised its holdings in Syndax Pharmaceuticals by 15.5% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 16,293 shares of the company’s stock valued at $297,000 after buying an additional 2,191 shares during the last quarter. Finally, Sterling Capital Management LLC raised its holdings in Syndax Pharmaceuticals by 846.6% during the 3rd quarter. Sterling Capital Management LLC now owns 2,963 shares of the company’s stock valued at $56,000 after buying an additional 2,650 shares during the last quarter.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals is a biotechnology company focused on developing and commercializing medicines for cancer and related serious diseases. Its research programs include therapies that target cancer-driving pathways, including menin and the colony-stimulating factor 1 receptor (CSF-1R).

The company’s medicines include Revuforj (revumenib), approved in the United States for certain adults and children aged one year and older with relapsed or refractory acute leukemia involving a KMT2A translocation.